Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter Singleton who wrote (4082)	4/17/1998 1:19:00 AM
From: margie	of 6136

Here's looking at those numbers! Percentage Market 9/97 10/97 11/97 12/97 1/98 2/98 3/98 Viracept Market Share 27.87 28.17 29.15 29.94 29.78 29.72 30.22% Total scrips 37488 40830 40013 45682 45466 42132 48637 Crixivan 40.9 41.4 40.07 37.75 36.74 36.75 36.06% Total scrips 55000 60000 55000 57600 56088 52132 58032 Norvir 11.53 11.89 12.05 12.55 13.308 13.43 13.73% Total scrips15500 17233 16543 19144 20316 19054 22104 Fortovase n/a n/a 0.70% 4% 6.5% 8.5 10.23% Total scrips 1000 6153 9990 12068 16471 Invirase 19.67 18.54 18 13.62 13.62 11.6 9.76% Total scrips26443 26865 24715 23987 20785 16453 15707 Invirase Plus Fortovase n/a n\a 18.73 19.76 20.16 20.108 19.99% Total Scripts 30140 30775 28521 32178 TOTAL* 134,431 144,928 137.271 152566 152655 141,839 160,951 And I made a mistake, It was Viracept's month to month prescription growth that was close to 5%, from February to March, not it's market share. Sorry. (4.8% according to PW) I'll post the month over month adjusted growth rates tomorrow.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next